ABILITA BIO NEWS
June 1, 2023
Abilita Bio changes name to Abilita Therapeutics and appoints Joel Edwards as chief business officer
Name change to Abilita Therapeutics reflects the company’s focus and newly established capabilities to build an internal pipeline of first- and best-in-class therapeutics.
Abilita Therapeutics strengthens leadership team by appointing Joel Edwards as chief business officer to advance corporate strategy and partnering efforts.
May 9, 2023
Abilita Bio to showcase Enabled Membrane Protein technologies at PEGS Boston conference
On the heels of a $7.5m financing round, the company will present its breakthrough platform technologies that are empowering the development of membrane protein-targeted treatments.
February 23, 2022
Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors
Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors. Mr. Bradbury is a seasoned biotech executive and business strategist with a formidable track record of building successful biotech companies. His guidance will be key to growing the leadership team, crafting our approach, and building a solid clinical development plan.